Please provide your email address to receive an email when new articles are posted on . The dosing interval can be safely extended to every 3 weeks in patients with rheumatoid arthritis on a regimen ...
NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
Fatigue is a high-priority symptom in patients with rheumatoid arthritis (RA), owing to its markedly detrimental effects on quality of life. Nonetheless, fatigue is rarely assessed by rheumatologists ...
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy. We report three patients with sight threatening uveitis that ...
Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...
ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® ...
HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others. Samsung Bioepis Co., Ltd. and Organon & Co. announced that the FDA has accepted ...
In this section, we summarize the evidence on clinical effectiveness on the basis of the continuation of adalimumab therapy beyond RCTs, or in registry studies. OLT 3 (DE029) Healthy male and female ...
Feb. 10, 2004 (Washington) — Adalimumab appears to be safe and effective in a dose-related manner for the treatment of chronic moderate to severe plaque psoriasis, new research suggests. Adalimumab, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results